<DOC>
	<DOCNO>NCT01778439</DOCNO>
	<brief_summary>This open-label Phase 1a dose escalation study single-agent OMP-52M51 subject relapse refractory solid tumor . Study include dose escalation phase expansion phase . Subjects assess safety , immunogenicity , pharmacokinetics , biomarkers , efficacy .</brief_summary>
	<brief_title>A Dose Escalation Study OMP-52M51 Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects must meet follow criterion eligible study : 1 . Age &gt; 18 year 2 . ECOG performance status &lt; 2 ( see Appendix B ) 3 . Solid tumor malignancy remain standard therapy either refuse consider candidate remain standard therapy . 4 . Must tumor measurable evaluable per RECIST v1.1 dose escalation phase . In expansion cohort ( ) , subject must measurable disease . 5 . Subjects must FormalinFixed , ParaffinEmbedded ( FFPE ) tissue available either archived fresh core punch needle biopsied study entry ( two fresh cores/punches prefer whenever possible ) determination Notch1 pathway activation status . 6 . Must receive last chemotherapy , biologic , radiotherapy , investigational therapy least 4 week prior enrollment ; 6 week last regimen include BCNU mitomycin C. 7 . Subjects must normal organ marrow function define : Absolute neutrophil count &gt; 1500/mL without growth factor support past 7 day Platelets &gt; 100,000/mL without transfusion past 7 day Total bilirubin &lt; 1.5 X institutional upper limit normal ( ULN ) ( &lt; 2X ULN subject Gilbert 's syndrome ) AST ( SGOT ) ALT ( SGPT ) &lt; 3 X institutional ULN ( subject hepatic involvement &lt; 5 X institutional ULN associate elevated bilirubin ) PT/INR aPTT within 1.5 X institutional ULN Creatinine &lt; 1.5 X institutional ULN OR Creatinine clearance &gt; 60 mL/min/1.73 m2 subject creatinine level institutional normal Normal Ejection Fraction ( &gt; 50 % ) ECHO scan MUGA 8 . Women childbearing potential must prior hysterectomy negative serum pregnancy test use adequate contraception prior study entry must agree use adequate contraception study entry least 6 month discontinuation study drug . Men must also agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry study entry least 6 month discontinuation study drug . Should woman enrol study female partner man enrol study become pregnant suspect pregnant participate study within 6 month discontinuation study , inform Investigator immediately . 9 . Ability understand willingness sign write informed consent document Subjects meet follow criterion eligible participation study : 1 . Currently receive therapeutic treatment malignancy include investigational agent 2 . Prior treatment gamma secretase inhibitor Notch 1 inhibitor 3 . Uncontrolled seizure disorder , active neurologic disease , active CNS involvement except individual previouslytreated CNS metastasis , asymptomatic , requirement high dos corticosteroid ( &gt; prednisone 10mg orally per day ) antiseizure medication least 4 week prior first dose study drug . 4 . History Grade 4 allergic reaction attribute humanized human monoclonal antibody therapy 5 . Significant intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 6 . Pregnant woman nurse woman 7 . Ongoing malignancy malignancy remission &lt; 3 year malignancy include trial . Patients history know squamous cell skin cancer within past 3 year include trial . The following prior malignancy allowable irrespective occur : situ carcinoma cervix , situ ductal breast cancer , lowgrade local bladder cancer . 8 . Subjects know HIV infection 9 . Known bleed disorder coagulopathy 10 . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel . 11 . Hemoptysis excess 2.5 mL ( onehalf teaspoon ) within 8 week first dose study drug . 12 . Subjects receive heparin , warfarin , similar anticoagulant , except subject low molecular weight heparin DVT/PE prophylaxis . Note : Subjects may receive lowdose aspirin and/or nonsteroidal antiinflammatory agent . 13 . New York Heart Association Classification II , III , IV ( see Appendix D ) 14 . Subjects poorly control blood pressure ( define systolic blood pressure ≥140 mmHg diastolic blood pressure ≥90 mmHg ) responsive medical therapy . Subjects take antihypertensive medication must take ≤2 medication obtain level blood pressure control . NOTE : Initiation adjustment antihypertensive medication ( ) permit prior study entry . 15 . Subjects ECG evidence ischemia ≥Grade 2 ventricular arrhythmia , subject history acute myocardial infarction within 6 month , subject unstable angina . 16 . Subjects know clinically significant gastrointestinal disease include , limited : inflammatory bowel disease active peptic ulcer disease know intraluminal metastatic lesion ( ) risk bleed history abdominal fistula , GI perforation , intraabdominal abscess within 28 day prior begin study treatment 17 . Subjects diarrhea time enrollment ongoing requirement anti diarrheal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>relapse refractory</keyword>
	<keyword>solid tumor</keyword>
</DOC>